Synthesis of 1,4-benzodiazepinones and 1,4benzoxazepinones via palladium-catalyzed amino and oxyacetoxylation

A.D. Manick, G. Duret, D.N. Tran, F. Berhal,* and G. Prestat*

Table of Contents

I. General Information	
II. General Procedure	S2
Preparation of substrates:	S2
Procedure for aminoacetoxylation reaction:	S5
Procedure for oxyacetoxylation reaction:	S5
Procedure for tosyl amine deprotection:	S6
III. Characterization of compounds	S6
IV. ¹ H and ¹³ C NMR spectra	

I. General Information

All reagents were purchased from chemical suppliers and used without further purification. Reactions were performed using freshly distilled solvents under an argon atmosphere. DCM was dried on calcium hydride. THF was dried on sodium/benzophenone. Dry DMF, DMSO, toluene, acetonitrile and dioxane were purchased from chemical suppliers. Analytical thin layer chromatography was performed on commercial silica gel plates 60F254. Flash column chromatography was performed on silica gel 60 (40-63 µm). NMR spectra were recorded on a 250 or 500 MHz spectrometer as specified. Chemical shifts (δ) are reported in ppm relative to tetramethylsilane (δ 0.00 ppm) or the CHCl₃ residual peak (δ 7.26) or the MeOH residual peak (δ 3.31) for ¹H NMR. Chemical shifts of ¹³C NMR are reported relative to CDCl₃ (δ 77.16) or CD₃OD (δ 49.00). Coupling constant (J) are reported in Hertz unit (Hz). Multiplicities are described with standard following abbreviations: s = singlet, br = broad, d = doublet, t = triplet, q = quadruplet, m = multiplet. Low resolution mass spectra (LRMS) were recorded with an ion trap mass analyzer under electrospray ionization (ESI) in positive or negative ionization mode detection or atmospheric pressure chemical ionization (APCI). High resolution mass spectra (HRMS) were recorded with a TOF mass analyzer under electrospray ionization (ESI) in positive or negative ionization mode detection, atmospheric pressure chemical ionization or atmospheric pressure photoionization (APPI). Melting points were measured on a Köfler bench. IR spectra were recorded on a FT-IR spectrophotometer, and the wavelengths reported in cm⁻¹.

II. General Procedure

Preparation of substrates:





- General procedure for the tosylation reaction:

The nitrogen tosylation of anthranilic acid derivatives was done using a reported procedure.¹ In a round bottom flask, 1.0 equiv. of Na₂CO₃ was dissolved in 70°C water (C = 1.1 mol/L). Then 1.2 equiv. of tosyl chloride was added followed by 1.0 equiv. of the desired anthranilic acid. The suspension was stirred at 70°C for 40 mn then at 85°C for 5 mn. The reaction mixture was then directly filtrated over Büchner and the solid washed with 85°C water. The filtrate was cooled to room temperature and then acidified to pH = 1 using an aqueous 6M HCl solution. The precipitated solid was collected by suction over Büchner and dried over vacuum. The resulting tosyl anthranilic acids were used without further purification.

- General procedure for the peptidic coupling:

In a round bottom flask, 1.2 equiv. of allyl benzylamine was placed in DCM (C = 0.67 mol/L) under argon. Then 1.0 equiv. of the desired tosyl anthranilic acid or salicylic acid were added, followed successively by 1.0 equiv. of EDC.HCl and 1.0 equiv. of HOBt. The clear solution was stirred at room temperature or reflux until starting material was totally consumed (monitored by TLC). The reaction mixture was then quenched with water. The aqueous layer was extracted with DCM (3 times). The combined organic phases were then dried with MgSO₄, filtrated and the solvent was removed under vacuum. The crude residue was purified by silica gel flash chromatography using Pentane/Et₂O as eluent (9:1 to 1:1). Rf of aniline derivatives were between 0.4 and 0.6 using Cyclohexane/AcOEt 1:1 as eluent. Rf of phenol derivatives were between 0.5 and 0.7 using Pentane/AcOEt 1:1 as eluent.

¹ M. D. Surman, M. J. Mulvihill, M. J. Miller, Org. Lett., 2002, 4, 139

- Preparation of *N*-allylbenzylamine:

The *N*-allylbenzylamine was synthesized using a reported procedure.² In a round bottom flask was placed at 0°C, 4.0 equiv. of MgSO₄ in dry DCM (C = 0.2 mol/L) under argon, then 1.0 equiv. of benzaldehyde was added, followed by 1.1 equiv. of allylamine. The suspension was stirred at room temperature for 24h, then the reaction mixture was filtrated over Büchner and the solvent was removed under vaccum. The crude imine was used directly without purification in the next step. The oily residue was dissolved in MeOH (C = 1 mol/L) and 2.0 equiv. of sodium borohydride were added by small portions at 0°C. The solution was stirred at room temperature for 2h, then the solvent was evaporated and the reaction was quenched carefully with a saturated aqueous solution of ammonium chloride. The aqueous phase was extracted with DCM (3 times) and the combined organic phases were then dried with MgSO₄, filtrated and the solvent was removed under vacuum. The resulting *N*-allylbenzylamine showed clean NMR spectra and was used without further purification.

- Preparation of *N*-benzylprop-2-yn-1-amine and *N*-benzylbut-2-yn-1-amine:

These two propargylic amines were prepared using a reported procedure.³ In a round bottom flask, under argon, was placed 6.0 equiv. of benzylamine. Then, 1.0 equiv. of the appropriate propargyl bromide was added dropwise and the orange solution was stirred at room temperature for 20h. The mixture was then diluted with water and Et₂O, the layers were separated and the organic one was washed using a saturated aqueous solution of sodium bicarbonate. After drying with MgSO₄ and filtration, the solvent was removed under vacuum. The crude residue was purified by silica gel flash chromatography using Cyclohexane/AcOEt as eluent (6:4).

Preparation of *N*-benzyl-3-phenylprop-2-yn-1-amine:

This propargylic amine was prepared using a reported procedure.⁴ In a round bottom flask, under argon, was placed 1.0 equiv. of iodobenzene followed by 4 mol% of CuI and 2 mol% of Pd(PPh₃)₂Cl₂ in NEt₃ (C = 1.5 mol/L). Then, a solution of 1.0 equiv. of *N*-Benzylprop-2-yn-1-amine in THF (C = 0.75 mol/L) was added and the suspension was stirred at room temperature for 45 mn. The reaction mixture was then filtrated on celite® and the solids washed with AcOEt.

² S. Kakaei, J. Xu, Org. Biomol. Chem., 2013, 11, 5481.

³ C. Molinaro, T. F. Jamison, J. Am. Chem. Soc., 2003, 125, 8076

⁴ H. V. Wachenfeldt, F. Paulsen, A. Sundin, D. Strand, Eur. J. Org. Chem., 2013, 4578.

After evaporation the crude residue was purified by silica gel flash chromatography using Cyclohexane/AcOEt as eluent (6:4). Rf was 0.4 using Cyclohexane/AcOEt 1:1 as eluent.

- Preparation of (Z)-*N*-benzylbut-2-en-1-amine and (Z)-*N*-benzyl-3-phenylprop-2-en-1-amine:

These alkenes were prepared using a reported procedure.⁵ In a dry round bottom flask were placed 0.25 equiv. (0.31 mmol) of nickel(II) acetate tetrahydrate in 0.6 mL of MeOH, followed by 0.25 equiv. (0.31 mmol) of sodium borohydride at 0°C. The suspension was stirred at room temperature for 15 mn. Then, 1.0 equiv. (1.24 mmol) of *N*-Benzylbut-2-yn-1-amine or *N*-Benzyl-3-phenylprop-2-yn-1-amine and 0.5 equiv. (0.62 mmol) of ethylene diamine in 4.0 mL of MeOH were added and the mixture was stirred under H₂ atmosphere at room temperature. After total consumption of starting material (monitored by TLC), the reaction was filtrated on celite® and the solids washed with AcOEt. The solvent was removed under vacuum and the crude residue was then purified by silica gel flash chromatography using AcOEt/MeOH as eluent (9/1).

Procedure for aminoacetoxylation reaction:

In a dry schlenk tube were placed, 1.0 equiv. (0.2 mmol) of alkenyl-amide **1**, followed by 10 mol% of Pd(OAc)₂ (0.02 mmol) and 2.5 equiv. (0.5 mmol) of iodosobenzene diacetate. The schlenk tube was flushed with argon, then dry DCM (C = 0.2 mol/L) was introduced and the solution was stirred for two minutes to achieve complete dissolution of starting materials. Finally, 1.0 equiv. (0.2 mmol) of DiPEA was added and the solution was stirred at room temperature. After total consumption of starting material (monitored by TLC), the reaction was quenched with a saturated aqueous solution of ammonium chloride. The aqueous phase was extracted with DCM (3 times). The combined organic phases were then dried with MgSO₄, filtrated and the solvent was removed under vacuum. The crude residue was purified by silica gel flash chromatography using Pentane/Et₂O as eluent (9:1 to 4:6). Rf of this set of compounds were between 0.3 and 0.5 using Cyclohexane/AcOEt 1:1 as eluent.

Procedure for oxyacetoxylation reaction:

In a dry schlenk tube were placed 1.0 equiv. (0.2 mmol) of alkenyl-amide **12**, followed by 10 mol% of $Pd(OAc)_2$ (0.02 mmol) and 2.5 equiv. (0.5 mmol) of iodosobenzene diacetate. The

⁵ G. Prestat, C. Baylon, M.-P. Heck, G. A. Grasa, S. P. Nolan, C. Mioskowski, J. Org. Chem., 2004, 69, 5770

schlenk tube was flushed with argon, then dry DMF (C = 0.2 mol/L) was introduced and the solution was stirred for two minutes to achieve complete dissolution of starting materials. Finally, 1.0 equiv. (0.2 mmol) of Bu₄NOAc was added and the solution was stirred at room temperature. After total consumption of starting material (monitored by TLC), the reaction was quenched with a saturated aqueous solution of ammonium chloride. The aqueous phase was extracted with DCM (3 times). The combined organic phases were then dried with MgSO₄, filtrated and the solvent was removed under vacuum. The crude residue was purified by silica gel flash chromatography using Pentane/Et₂O as eluent (7:3 to 2:8). Rf of this set of compounds were between 0.4 and 0.6 using Pentane/AcOEt 1:1 as eluent.

Procedure for tosyl amine deprotection:

In a dry round bottom flask were placed 20.0 equiv. (12.5 mmol) of magnesium turnings under argon, followed by a solution of 1.0 equiv. (0.625 mmol) of tosyl amine **2a** in MeOH (C = 0.045 mol/L). The suspension was vigorously stirred at room temperature for two hours. The grey-white reaction mixture was then diluted with DCM and a saturated aqueous solution of ammonium chloride. The two phases were separated and the aqueous one was extracted with DCM (4 times). The combined organic phases were washed 1 time with a saturated aqueous solution of sodium bicarbonate then dried with MgSO₄ and the solvent was removed under vacuum. The crude residue was then purified by silica gel flash chromatography using Pentane/AcOEt as eluent (3:7 to 0:1).

III. Characterization of compounds

N-Allylbenzylamine:

(known compound²) pale yellow oil, 80% Yield, ¹H NMR (CDCl₃, 500 MHz) δ 7.37 (d, J = 4.5 Hz, 4H), 7.30-7.25 (m, 1H), 5.97 (ddt, J = 16.5 Hz, J = 10.0 Hz, J = 5.5 Hz, 1H), 5.23 (dd, J = 17.0 Hz, J = 2.0 Hz, 1H), 5.16 (dd, J = 10.0 Hz, J = 1.0 Hz, 1H), 3.82 (s, 2H), 3.30 (d, J = 6.5 Hz, 2H), 1.80 (br s, 1H); ¹³C NMR (CDCl₃, 125 MHz) δ 140.2, 136.8, 128.5, 128.3, 127.1, 116.2, 53.3, 51.8.

N-Benzylprop-2-yn-1-amine:

² S. Kakaei, J. Xu, Org. Biomol. Chem., 2013, 11, 5481.

(known compound³) yellow oil, 83% Yield, ¹H NMR (CDCl₃, 500 H MHz) δ 7.48-7.21 (m, 5H), 3,90 (s, 2H), 3.44 (d, J = 2.5 Hz, 2H), 2.27 (t, J = 2.5 Hz, 1H), 1.62-1.46 (br s, 1H).

N-Benzylbut-2-yn-1-amine:

 $(\text{known compound}^{6}) \text{ yellow oil, 84\% Yield, }^{1}\text{H NMR (CDCl_3, 500 MHz)} \\ \delta 7.30-7.21 \text{ (m, 4H), 7.20-7.14 (m, 1H), 3,78 (s, 2H), 3,30 (q, J = 2.5 Hz, 2H), 1,77 (t, J = 2.5 Hz, 3H), 1.48-1.38 (br s, 1H); }^{13}\text{C NMR (CDCl_3, 125 MHz)} \delta 139.9, 128.5, 128.5, 127.2, 79.3, 77.3, 52.7, 38.0, 3.6.}$

N-Benzyl-3-phenylprop-2-yn-1-amine:

 $\begin{array}{c} (\text{known compound}^4) \text{ yellow oil, 96\% Yield, }^1\text{H NMR (CDCl_3, 250 MHz)} \\ \delta \ 7.52\text{-}7.43 \ (\text{m, 2H}), \ 7.42\text{-}7.25 \ (\text{m, 8H}), \ 3.96 \ (\text{s, 2H}), \ 3.66 \ (\text{s, 2H}), \ 1.71\text{-} \\ 1.51 \ (\text{br s, 1H}); \ ^{13}\text{C NMR (CDCl_3, 125 MHz)} \ \delta \ 139.7, \ 131.8, \ 128.6, \ 128.4, \ 128.2, \ 127.3, \ 123.4, \\ 87.7, \ 83.9, \ 52.7, \ 38.4; \ \text{MS (ESI)}: \ \text{m/z} = 222.2 \ [\text{M+H}^+]; \ \text{IR} \ (\nu = \text{cm}^{-1}): \ 3342, \ 3055, \ 3026, \ 2920, \\ 2844, \ 1952, \ 1885, \ 1598, \ 1488, \ 1450, \ 1438, \ 1103. \end{array}$

(Z)-*N*-Benzylbut-2-en-1-amine:

(known compound⁷) yellow oil, 91% Yield, ¹H NMR (CDCl₃, 500 MHz) δ N Ph 7.32 (d, J = 4.5 Hz, 4H), 7.26-7.20 (br s, 1H), 5.69-5.46 (m, 2H), 3.90-3.70 (br s, 2H), 3.40-3.23 (br s, 2H), 1.62 (d, J = 6.0 Hz, 3H).

(Z)-*N*-Benzyl-3-phenylprop-2-en-1-amine:

Ph (known compound⁸) orange oil, 80% Yield, ¹H NMR (CDCl₃, 250 MHz) δ 7.35-7.13 (m, 10H), 6.52 (d, J = 11.75 Hz, 1H), 5.79 (td, J = 11.75 Hz, J = 6.5 Hz, 1H), 3.75 (s, 2H), 3.53 (d, J = 6.0 Hz, 2H); ¹³C NMR (CDCl₃, 125

MHz) & 139.8, 137.1, 131.1, 130.7, 128.9, 128.8, 128.7, 128.6, 128.5, 128.4, 128.3, 127.2, 127.0, 126.4, 53.5, 46.9.

³ C. Molinaro, T. F. Jamison, J. Am. Chem. Soc., 2003, 125, 8076

⁶ Y. Hirata, T. Yukawa, N. Kashihara, Y. Nakao, T. Hiyama, J. Am. Chem. Soc., 2009, 131 10964.

⁴ H. V. Wachenfeldt, F. Paulsen, A. Sundin, D. Strand, Eur. J. Org. Chem., 2013, 4578.

⁷ J. Blid, P. Brandt, P. Somfai, J. Org. Chem., 2004, **69**, 3043.

⁸ B. C. Ranu, A. Majee, A. Sarkar, J. Org. Chem., 1998, 63, 370.

2-((4-Methylphenyl)sulfonamido)benzoic acid:

(known compound¹) white solid, 80% Yield, ¹H NMR (CD₃OD, 500 MHz) δ (known compound¹) white solid, 80% Yield, ¹H NMR (CD₃OD, 500 MHz) δ 7.93 (dd, J = 8.0 Hz, J = 1.5 Hz, 1H), 7.67-7.64 (m, 3H), 7.48-7.44 (m, 1H), 7.26 (d, J = 8.0 Hz, 2H), 7.06 (t, J = 7.5 Hz, 1H), 2.34 (s, 3H); ¹³C NMR (CD₃OD, 125 MHz) δ 171.4, 145.6, 141.8, 137.5, 135.2, 132.8, 130.7, 128.4, 124.3, 120.4, 118.4, 21.4; MS (ESI) : m/z = 291.9 [M+H⁺]; HRMS (ESI) : m/z calcd for C₁₄H₁₂O₄NS [M-H⁺] 290.04925, found 290.04883; IR (v = cm⁻¹) : 3203, 3069, 2997, 1673, 1492; mp : 224-228°C.

5-Methyl-2-((4-methylphenyl)sulfonamido)benzoic acid:

 $\begin{array}{l} \text{(known compound⁹) white solid, 88\% Yield, ^1H NMR (CD_3OD, 500 MHz) } \delta \\ \text{(CO}_2H \\ \hline CO_2H \\ \hline CO_2H$

3-((4-Methylphenyl)sulfonamido)-2-naphthoic acid:

(known compound¹⁰) brown solid, 86% Yield, ¹H NMR (CD₃OD, 500 MHz) δ 8.56 (s, 1H), 8.01 (s, 1H), 7.83 (d, *J* = 8.0 Hz, 1H), 7.78 (d, *J* = 8.5 Hz, 1H), 7.66 (d, *J* = 8.5 Hz, 2H), 7.57 (t, *J* = 7.5 Hz, 1H), 7.43 (t, *J* = 7.5 Hz, 1H), 7.21 (d, *J* = 8.5 Hz, 2H), 2.29 (s, 3H); ¹³C NMR (CD₃OD, 125 MHz) δ 171.1, 145.6, 137.3, 137.2, 136.7, 135.0, 130.6, 130.6, 130.5, 130.1, 128.4, 128.1, 127.0, 118.4, 118.2, 21.4; MS (ESI) : m/z = 341.9 [M+H⁺]; HRMS (ESI) : m/z calcd for C₁₈H₁₄O₄NS [M-H⁺] 340.06490, found 340.06445; IR (v = cm⁻¹) : 3204, 3008, 2889, 1677, 1282; mp : 224-228°C.

4-Methoxy-2-((4-methylphenyl)sulfonamido)benzoic acid:

NHTs (known compound¹¹) white solid, 75% Yield, ¹H NMR (CD₃OD, 500 MHz) δ 7.87 (d, J = 8.5 Hz, 1H), 7.69 (d, J = 8.5 Hz, 2H), 7.27 (d, $J = CO_2H$

MeO

¹ M. D. Surman, M. J. Mulvihill, M. J. Miller, Org. Lett., 2002, 4, 139

⁹ M. R. Yadav, R. K. Rit, A. K. Sahoo, Org. Lett., 2013, 15, 1638

¹⁰ W. F. Beech, N. Legg, J. Chem. Soc., 1950, 961

¹¹ W. N. Speckamp, U. K. Pandit, H. O. Huisman, Recl. Trav. Chim. Pays Bas, 82, 39

8.0 Hz, 2H), 7.14 (d, J = 2.5 Hz, 1H), 6.58 (dd, J = 8.5 Hz, J = 2.5 Hz, 1H), 3.79 (s, 3H), 2.34 (s, 3H); ¹³C NMR (CD₃OD, 62.5 MHz) δ 172.0, 165.2, 145.6, 143.6, 137.4, 134.7, 134.2, 130.7, 128.3, 109.9, 104.7, 56.0, 21.4; MS (ESI) : m/z = 320.1 [M-H⁺]; HRMS (ESI) : m/z calcd for C₁₅H₁₄O₅NS [M-H⁺] 320.05960, found 320.05982; IR (v = cm⁻¹) : 3214, 2925, 1654, 1161; mp : 230-234°C.

5-Methoxy-2-((4-methylphenyl)sulfonamido)benzoic acid:

 $\begin{array}{l} \mbox{MeO} \qquad \qquad \mbox{NHTs} \\ \mbox{MeO} \qquad \qquad \mbox{MeO} \qquad \mbox{MeO} \qquad \mbox{MeO} \qquad \qquad \mbox{MeO} \mb$

4,5-Dimethoxy-2-((4-methylphenyl)sulfonamido)benzoic acid:

 $\begin{array}{l} \mbox{MeO} \qquad \mbox{NHTs} & (known \ compound^{12}) \ beige \ solid, \ 57\% \ Yield, \ ^1H \ NMR \ (CD_3OD, \ 500 \ MHz) \ \delta \ 7.63 \ (d, \ J = 8.0 \ Hz, \ 2H), \ 7.38 \ (s, \ 1H), \ 7.30-7.25 \ (m, \ 3H), \ 3.87 \ (s, \ 3H), \ 3.75 \ (s, \ 3H), \ 2.35 \ (s, \ 3H); \ ^{13}C \ NMR \ (CD_3OD, \ 125 \ MHz) \ \delta \ 171.0, \ 155.3, \ 146.4, \ 145.6, \ 137.3, \ 137.2, \ 130.7, \ 128.4, \ 114.6, \ 104.6, \ 56.6, \ 56.5, \ 21.4; \ MS \ (ESI) : \ m/z \ = \ 351.9 \ [M+H^+]; \ HRMS \ (ESI) : \ m/z \ calcd \ for \ C_{16}H_{16}O_6NS \ [M-H^+] \ 350.07038, \ found \ 350.07004; \ IR \ (v = cm^{-1}) : \ 3188, \ 3049, \ 2992, \ 1648, \ 1268; \ mp : \ 218-222^{\circ}C. \end{array}$

4-Chloro-2-((4-methylphenyl)sulfonamido)benzoic acid:

 $\begin{array}{c} \mathsf{Cl} \qquad \mathsf{NHTs} \qquad (\text{known compound}^{13}) \text{ white solid, } 68\% \text{ Yield, } ^1\text{H} \text{ NMR (CD}_3\text{OD, } 500 \\ \text{MHz}) \ \delta \ 7.85 \ (\text{d}, \ J = 9.0 \ \text{Hz}, 1\text{H}), \ 7.67 \ (\text{d}, \ J = 8.5 \ \text{Hz}, 2\text{H}), \ 7.63 \ (\text{d}, \ J = 2.5 \ \text{Hz}, 1\text{H}), \ 7.26 \ (\text{d}, \ J = 8.0 \ \text{Hz}, 2\text{H}), \ 7.00 \ (\text{dd}, \ J = 9.0 \ \text{Hz}, \ J = 2.5 \ \text{Hz}, 1\text{H}), \ 2.31 \ (\text{s}, 3\text{H}); \ ^{13}\text{C} \text{ NMR (CD}_3\text{OD, } 125 \ \text{MHz}) \ \delta \ 170.5, \ 145.9, \ 142.9, \ 141.2, \ 137.1, \ 134.1, \ 130.8, \ 128.2, \ 124.2, \ 119.7, \ 116.2, \ 21.4; \ \text{MS (ESI)} : \ \text{m/z} = 325.8 \ [\text{M}+\text{H}^+]; \ \text{HRMS (ESI)} : \ \text{m/z} \ \text{calcd for} \end{array}$

¹² R. V. Coombs, R. P. Danna, M. Denzer, G. E. Hardtmann, B. Huegi, G. Koletar, J. Koletar, H. Ott, E. Jukniewicz, *J. Med. Chem.*, 1973, **16**, 1237

¹³ M. M. Krayushkin, B. V. Lichitskii, D. V. Pashchenko, I. A. Antonov, B. V. Nabatov, A. A. Dudinov, *Russ. J. Organ. Chem.* 2007, **43**, 1357 and references cited.

 $C_{14}H_{11}O_4NCIS$ [M-H⁺] 324.01028, found 324.00980; IR (v = cm⁻¹) : 3182, 3031, 2823, 1672, 1160; mp : 200-204°C.

5-Bromo-2-((4-methylphenyl)sulfonamido)benzoic acid:

 $\begin{array}{l} \label{eq:solution} \text{NHTs} \\ \text{Br} & (\text{known compound}^{14}) \text{ white solid, 74\% Yield, ^1H NMR (CD_3OD, 500} \\ \text{MHz}) \, \delta \, 8.03-8.01 \ (\text{m}, 1\text{H}), 7.67 \ (\text{td}, J = 8.5 \ \text{Hz}, J = 1.5 \ \text{Hz}, 2\text{H}), 7.61-7.59 \\ \text{(m}, 2\text{H}), 7.31-7.28 \ (\text{m}, 2\text{H}), 2.36 \ (\text{s}, 3\text{H}); ^{13}\text{C NMR} \ (\text{CD}_3\text{OD}, 125 \ \text{MHz}) \, \delta \\ 169.9, 145.9, 140.9, 138.0, 137.2, 135.1, 130.8, 128.4, 122.3, 119.8, 116.7, 21.4; \ \text{MS} \ (\text{ESI}) : \\ \text{m/z} = 369.8 \ [\text{M}+\text{H}^+]; \ \text{HRMS} \ (\text{ESI}) : \ \text{m/z} \ \text{calcd for } \text{C}_{14}\text{H}_{11}\text{O}_4\text{NBrS} \ [\text{M}-\text{H}^+] \ 367.9598, \ \text{found} \\ 367.9587; \ \text{IR} \ (\nu = \text{cm}^{-1}) : 3065, 2872, 1662, 1162; \ \text{mp} : 198-200^{\circ}\text{C}. \end{array}$

2-((4-Methylphenyl)sulfonamido)-4-nitrobenzoic acid:

 O_2N (known compound¹⁵) brown solid, 71% Yield, ¹H NMR (CD₃OD, 250 MHz) δ 8.46 (d, J = 2.0 Hz, 1H), 8.16 (d, J = 9.0 Hz, 1H), 7.85 (dd, J = 6.0 Hz, J = 2.0 Hz, 1H), 7.74 (d, J = 8.0 Hz, 2H), 7.32 (d, J = 8.25 Hz, 2H), 2.35 (s, 3H); MS (ESI) : m/z = 335.2 [M-H⁺]; HRMS (ESI) : m/z calcd for C₁₄H₁₁O₆N₂S [M-H⁺] 335.03433, found 335.03366; IR (v = cm⁻¹) : 3224, 3108, 2860, 1702, 1531, 1157. mp : 200-204°C.

N-Allyl-*N*-benzyl-2-((4-methylphenyl)sulfonamido)benzamide (**1a**):



beige solid, 74% Yield, ¹H NMR (CDCl₃, 500 MHz) δ 8.52-8.23 (br s, 1H), 7.68 (d, *J* = 5.0 Hz, 2H), 7.42-6.88 (m, 11H), 5.88-5.54 (br s, 1H), 5.28 (d, *J* = 10.5 Hz, 1H), 5.14 (d, *J* = 17.5 Hz, 1H), 4.70-3.19 (br m, 4H), 2.47-2.20 (br s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.3, 143.6, 136.2, 132.7, 131.2, 129.6, 129.1, 128.1, 127.3, 127.0, 126.6, 124.0, 123.3, 118.8, 50.3, 47.5, 21.6; MS (ESI) : m/z = 421.0 [M+H⁺]; HRMS (ESI) : m/z calcd for C₂₄H₂₃O₃N₂S

 $[M-H^+]$ 419.14349, found 419.14264; $IR (v = cm^{-1})$: 3027, 2988, 2920, 2899, 1620, 1163; mp : 76-80°C.

N-Allyl-*N*-benzyl-5-methyl-2-((4-methylphenyl)sulfonamido)benzamide (**1b**):

¹⁴ P. Wangtrakuldee, M. S. Byrd, C. G. Campos, M. W. Henderson, Z. Zhang, M. Clare, A. Masoudi, P. J. Myler,

J. R. Horn, P. A. Cotter, T. J. Hagen, ACS Med. Chem. Lett., 2013, 4, 699

¹⁵ E. H. Charlesworth, P. Mathiaparanam, Can. J. Chem., 1968, 46, 463



white solid, 75% Yield, ¹H NMR (CDCl₃, 500 MHz) δ 8.28-8.08 (br m, 1H), 7.78-6.73 (br m, 12H), 5.89-5.54 (br m, 1H), 5.28 (d, *J* = 10.0 Hz, 1H), 5.13 (dd, *J* = 17.5 Hz, *J* = 1.5 Hz, 1H), 4.71-3.10 (br m, 4H), 2.51-1.98 (br m, 6H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.3, 143.4, 136.6, 134.1, 133.4, 132.7, 131.8, 129.5, 129.0, 128.1, 127.4, 127.3, 123.8, 118.8, 50.3, 47.4, 21.5, 20.8; MS (ESI) : m/z = 435.0 [M+H⁺]; HRMS (ESI) : m/z calcd

for C₂₅H₂₇O₃N₂S [M+H⁺] 435.17369, found 435.17346; IR ($\nu = cm^{-1}$) : 3026, 2917, 2855, 1620, 1383, 1165; mp : 138-140°C.

N-Allyl-*N*-benzyl-3-((4-methylphenyl)sulfonamido)-2-naphthamide (**1c**):



white solid, 61% Yield, ¹H NMR (CDCl₃, 500 MHz) δ 8.48-8.27 (br s, 1H), 8.15-8.03 (br s, 1H), 7.86-7.60 (br m, 4H), 7.57-7.31 (br m, 8H), 7.24-7.07 (br m, 1H), 6.90-6.76 (br s, 1H), 5.97-5.61 (br s, 1H), 5.33 (d, J = 10.5 Hz, 1H), 5.19 (dd, J = 17.0 Hz, J = 1.0 Hz, 1H), 4.82-3.17 (br m, 4H), 2.48-2.13 (br s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.3, 143.5, 136.7, 134.3, 132.7, 132.4, 129.7, 129.6, 129.4, 129.1, 128.2,

127.9, 127.5, 127.3, 127.2, 126.4, 121.2, 118.7, 117.2, 50.5, 47.7, 21.5; MS (ESI) : m/z = 471.1 [M+H⁺]; HRMS (ESI) : m/z calcd for C₂₈H₂₇O₃N₂S [M+H⁺] 471.17369, found 471.17371; IR ($\nu = cm^{-1}$) : 3155, 3046, 2984, 1623, 1353, 1145; mp : 125-129°C.

N-Allyl-*N*-benzyl-4-methoxy-2-((4-methylphenyl)sulfonamido)benzamide (1d):



white solid, 74% Yield, ¹H NMR (CDCl₃, 500 MHz) δ 9.31-8.38 (br s, 1H), 7.86-6.72 (br m, 11H), 6.53 (s, 1H), 5.89-5.51 (br s, 1H), 5.28 (d, J = 10.0 Hz, 1H), 5.15 (d, J = 17.0 Hz, 1H), 4.82-4.15 (br s, 2H), 3.80 (s, 3H), 3.71-2.90 (br s, 2H), 2.30 (s, 3H); ¹³C NMR (CDCl₃, 62.5 MHz) δ 170.5, 161.6, 143.5, 138.5, 136.4, 136.3, 132.4, 129.5, 128.8, 128.5, 127.8, 127.1, 118.6, 117.7, 109.8, 108.2, 55.5, 49.9, 49.7, 21.4;

 $MS \ (ESI): m/z = 451.1 \ [M+H^+]; \ HRMS \ (ESI): m/z \ calcd \ for \ C_{25}H_{27}O_4N_2S \ [M+H^+] \ 451.16860, \\ found \ 451.16904; \ IR \ (\nu = cm^{-1}): \ 3173, \ 3018, \ 2972, \ 2920, \ 1623, \ 1294, \ 1159; \ mp = 131-133^{\circ}C.$

N-Allyl-*N*-benzyl-5-methoxy-2-((4-methylphenyl)sulfonamido)benzamide (**1e**):



white solid, 64% Yield, ¹H NMR (CDCl₃, 250 MHz) δ 8.30-7.98 (br m, 1H), 7.70-6.55 (br m, 12H), 5.90-5.55 (br m, 1H), 5.31 (d, *J* = 10.25 Hz, 1H), 5.16 (d, *J* = 17.0 Hz, 1H), 4.68-2.95 (br m, 7H), 2.50-2.10 (br m, 3H); ¹³C NMR (CDCl₃, 62.5 MHz) δ 169.6, 156.2, 143.1, 136.2, 132.5, 129.6, 129.3, 128.7, 128.1, 127.9, 127.0, 126.6, 126.2, 125.9, 118.3, 116.3, 111.8, 110.7, 55.5, 49.6, 47.3, 21.3; MS (ESI) : m/z =

451.1 [M+H⁺]; IR (v = cm⁻¹) : 3166, 2976, 2899, 1628, 1289, 1161; mp : 136-138°C.

N-Allyl-*N*-benzyl-4,5-dimethoxy-2-((4-methylphenyl)sulfonamido)benzamide (1f):



white solid, 71% Yield, ¹H NMR (CDCl₃, 500 MHz) δ 8.90-8.36 (br s, 1H), 7.67-6.50 (m, 11H), 5.81-5.66 (br s, 1H), 5.30 (d, *J* = 9.0 Hz, 1H), 5.17 (d, *J* = 13.5 Hz, 1H), 4.80-2.80 (br m, 10H), 2.51-2.08 (br s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.6, 151.1, 145.4, 143.4, 136.7, 136.5, 132.7, 130.9, 129.6, 129.1, 127.9, 127.4, 118.5, 118.3, 109.5,

108.5, 56.3, 49.6, 49.5, 21.6; MS (ESI) : $m/z = 481.2 [M+H^+]$; HRMS (ESI) : m/z calcd for C₂₆H₂₉O₅N₂S [M+H⁺] 481.17917, found 481.17935; IR ($\nu = cm^{-1}$) : 3049, 2974, 2904, 1600, 1520, 1352, 1163; mp : 124-128°C.

N-Allyl-*N*-benzyl-4-chloro-2-((4-methylphenyl)sulfonamido)benzamide (**1g**):



white solid, 59% Yield, ¹H NMR (CDCl₃, 500 MHz) δ 8.68-8.32 (br s, 1H), 7.80-6.75 (br m, 12H), 5.87-5.48 (br s, 1H), 5.28 (d, *J* = 10.0 Hz, 1H), 5.14 (d, *J* = 17.5 Hz, 1H), 4.73-3.13 (br m, 4H), 2.54-2.13 (br s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 169.6, 143.9, 137.7, 137.2, 136.4, 132.3, 129.9, 129.8, 129.4, 129.1, 128.2, 128.0, 127.3, 124.1, 122.9, 118.9, 50.3, 47.7, 21.6; MS (ESI) : m/z = 455.1 [M+H⁺]; HRMS (ESI) : m/z calcd for

 $C_{24}H_{24}O_3N_2ClS [M+H^+] 455.11907$, found 455.11966; IR ($\nu = cm^{-1}$) : 3077, 2927, 2855, 1622, 1167; mp : 122-126°C.

N-Allyl-*N*-benzyl-5-bromo-2-((4-methylphenyl)sulfonamido)benzamide (1h):



white solid, 57% Yield, ¹H NMR (CDCl₃, 500 MHz) δ 8.36-8.12 (br s, 1H), 7.88-6.72 (br m, 12H), 5.92-5.53 (br s, 1H), 5.31 (d, *J* = 10.0 Hz, 1H), 5.15 (d, *J* = 17.5 Hz, 1H), 4.80-3.07 (br m, 4H), 2.56-2.14 (br s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 168.7, 143.9, 136.4, 136.3, 135.2, 134.0, 132.1, 129.8, 129.6, 129.5, 129.4, 129.1, 128.2, 127.3, 125.0, 119.1, 117.2, 50.2, 47.7, 21.6; MS (ESI) : m/z = 500.1 [M+H⁺]; HRMS (ESI) :

m/z calcd for C₂₄H₂₄O₃N₂BrS [M+H⁺] 499.06855, found 499.06860; IR ($\nu = cm^{-1}$) : 3013, 2925, 1624, 1378, 1164; mp : 144-148°C.

N-Allyl-*N*-benzyl-2-((4-methylphenyl)sulfonamido)-4-nitrobenzamide (1i):



white solid, 45% Yield, ¹H NMR (CDCl₃, 500 MHz) δ 8.58-8.19 (br m, 2H), 7.97-7.51 (br m, 3H), 7.51-6.92 (br m, 8H), 5.91-5.54 (br m, 1H), 5.31 (d, *J* = 10.5 Hz, 1H), 5.18 (d, *J* = 17.0 Hz, 1H), 4.80-3.27 (br m, 4H), 2.54-2.24 (br s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 168.4, 149.2, 144.5, 137.5, 136.1, 131.9, 130.2, 130.0, 129.2, 128.4, 127.7, 127.4, 126.6, 119.2, 118.4, 116.8, 50.3, 47.9, 21.7; MS (ESI) : m/z = 466.1

 $[M+H^+]$; HRMS (ESI) : m/z calcd for C₂₄H₂₄O₅N₃S $[M+H^+]$ 466.14312, found 466.14377; IR ($\nu = cm^{-1}$) : 3060, 2948, 2861, 1622, 1530, 1164; mp : 128-130°C.

N-Allyl-*N*-benzyl-2-((4-methylphenyl)sulfonamido)-5-nitrobenzamide (**1j**):



pale yellow solid, 42% Yield, ¹H NMR (CDCl₃, 500 MHz) δ 8.94-8.77 (br s, 1H), 8.25-8.04 (br m, 2H), 7.79 (d, *J* = 8.0 Hz, 1H), 7.74-7.53 (br s, 2H), 7.50-7.29 (br m, 5H), 7.22-6.96 (br s, 2H), 5.95-5.56 (br m, 1H), 5.35 (d, *J* = 10.0 Hz, 1H), 5.20 (dd, *J* = 17.0 Hz, *J* = 1.0 Hz, 1H), 4.84-3.34 (br m, 4H), 2.34 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 168.3, 144.7, 142.6, 142.4, 136.2, 131.7, 130.1, 129.3, 128.4, 127.3, 126.5,

123.0, 119.5, 50.7, 48.2, 21.7; HRMS (ESI) : m/z calcd for $C_{24}H_{24}O_5N_3S$ [M+H⁺] 466.14312, found 466.14340; IR (v = cm⁻¹) : 3070, 2966, 2927, 2853, 1654, 1165; mp : 130-134°C.

(Z)-*N*-Benzyl-*N*-(but-2-en-1-yl)-2-((4-methylphenyl)sulfonamido)benzamide (1k):



Ţs

white foam, 71% Yield, ¹H NMR (CDCl₃, 500 MHz) δ 8.52-8.18 (br s, 1H), 7.84-6.71 (m, 13H), 5.84-5.41 (br s, 1H), 5.46-5.16 (br s, 1H), 4.84-2.97 (br m, 4H), 2.49-2.09 (br m, 3H), 1.61-1.21 (br s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.1, 143.5, 136.6, 136.1, 131.0, 130.9, 129.8, 129.7, 129.6, 129.2,

128.9, 128.6, 128.6, 128.0, 127.3, 125.2, 124.2, 123.9, 123.6, 122.6, 47.7, 44.8, 21.5, 13.0; MS (ESI) : m/z = 435.3 [M+H⁺].

(Z)-*N*-Benzyl-2-((4-methylphenyl)sulfonamido)-N-(3-phenylallyl)benzamide (11):

pale yellow foam, 89% Yield, ¹H NMR (CDCl₃, 250 MHz) δ 8.56-8.36 (br s, 1H), 7.83-6.74 (m, 18H), 6.66 (d, *J* = 11.5 Hz, 1H), 5.60 (td, *J* = 11.5Hz, *J* = 6.5Hz, 1H), 4.68-3.41 (m, 4H), 2.41-2.06 (br s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 169.8, 143.5, 136.3, 136.0, 133.3, 131.1, 129.5, 128.9, 128.8,

 $128.7, 128.5, 128.4, 128.0, 127.6, 127.3, 126.7, 126.2, 124.1, 123.5, 47.9, 45.9, 21.6; \text{MS} (\text{ESI}): m/z = 495.3 \text{ [M-H^+]}.$

N-Allyl-*N*-benzyl-2-hydroxybenzamide (**12a**):

white solid, 42% Yield, ¹H NMR (CDCl₃, 500 MHz) δ 9.89 (s, 1H), 7.42-7.34 (m, 3H), 7.34-7.27 (m, 4H), 7.02 (dd, J = 8.0 Hz, J = 1.0 Hz, 1H), 6.78 (t, J = 7.5 Hz, 1H), 5.95-5.86 (m, 1H), 5.34 (d, J = 10.0 Hz, 1H), 5.25 (d, J = 17.0 Hz, 1H), 4.76 (s, 2H), 4.05 (d, J = 5.5 Hz, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ 172.6, 159.4, 136.5, 133.0, 132.6, 129.0, 127.8, 127.7, 127.6, 118.7, 118.5,

118.3, 117.2, 50.2, 50.1; IR ($\nu = cm^{-1}$) : 3133, 3083, 2978, 1607, 1577, 1453, 739, mp : 94-98°C.

N-Allyl-*N*-benzyl-2-hydroxy-5-methylbenzamide (**12b**):



White solid, 68% Yield; ¹H NMR (CDCl₃, 500 MHz) δ 9.59-9.33 (br s, 1H), 7.40-7.34 (m, 2H), 7.34-7.27 (m, 3H), 7.18-7.10 (m, 2H), 6.92 (d, *J* = 8.0 Hz, 1H), 5.95-5.84 (m, 1H), 5.33 (d, *J* = 10.5 Hz, 1H), 5.25 (d, *J* = 17.5 Hz, 1H), 4.74 (s, 2H), 4.05 (d, *J* = 5.5 Hz, 2H), 2.18 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 172.6, 156.8, 136.6, 133.6, 132.7, 128.9, 127.8,

127.7, 127.7, 118.5, 117.9, 117.2, 50.3, 50.1, 20.6; IR (v = cm⁻¹) : 3059, 3033, 2921, 1602, 1577, 1483, 816; mp : 118-122°C.

N-Allyl-*N*-benzyl-2-hydroxy-3-methylbenzamide (**12c**):



116.5, 50.2, 50.1, 16.1; IR (v = cm⁻¹) : 3063, 3030, 2978, 2921, 2857, 1602, 1580, 1428, 1249, 760.

N-Allyl-*N*-benzyl-2-hydroxy-5-methoxybenzamide (**12d**):



White solid, 61% Yield, ¹H NMR (CDCl₃, 500 MHz) δ 9.50-8.95 (br s, 1H), 7.42-7.34 (m, 2H), 7.34-7.27 (m, 3H), 6.98-6.89 (m, 2H), 6.89-6.82 (br s, 1H), 5.98-5.87 (m, 1H), 5.35 (d, *J* = 10.5 Hz, 1H), 5.27 (d, *J* = 17.5 Hz, 1H), 4.75 (s, 2H), 4.07 (d, *J* = 5.5 Hz, 2H), 3.51 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 172.4, 153.0, 151.8, 136.6, 132.6, 129.1,

127.8, 127.5, 120.0, 119.0, 118.5, 117.3, 111.4, 55.7, 50.2, 50.1; IR (v = cm⁻¹) : 3145, 3075, 2993, 2951, 2828, 1588, 1580, 1487, 731; mp : 96-98°C.

N-Allyl-*N*-benzyl-5-chloro-2-hydroxybenzamide (**12e**):



White solid, 72% Yield, ¹H NMR (CDCl₃, 500 MHz) δ 8.60-8.20 (br s, 1H), 7.42-7.35 (m, 2H), 7.34-7.27 (m, 4H), 7.20 (dd, J = 9.0 Hz, J = 2.5 Hz, 1H), 6.90 (d, J = 9.0 Hz, 1H), 5.94-5.80 (m, 1H), 5.33 (d, J = 10.0 Hz, 1H), 5.25 (d, J = 17.5 Hz, 1H), 4.73 (s, 2H), 4.00 (d, J = 5.0 Hz, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.9, 156.1, 136.1, 132.3, 132.0, 128.9,

127.9, 127.8, 127.7, 127.0, 123.6, 120.4, 119.3, 118.6, 50.0, 49.9; IR ($\nu = cm^{-1}$) : 3035, 3014, 2992, 2926, 1574, 1414, 1281, 820; mp : 113-115°C.

N-Allyl-*N*-benzyl-5-bromo-2-hydroxybenzamide (**12f**):



White solid, 67% Yield, ¹H NMR (CDCl₃, 500 MHz) δ 9.96-9.06 (br s, 1H), 7.47 (s, 1H), 7.41-7.35 (m, 3H), 7.35-7.25 (m, 3H), 6.86 (d, *J* = 9.0 Hz, 1H), 5.95-5.82 (m, 1H), 5.34 (d, *J* = 10.5 Hz, 1H), 5.26 (d, *J* = 17.5 Hz, 1H), 4.73 (s, 2H), 4.02 (d, *J* = 5.0 Hz, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.9, 157.0; 136.1, 135.1, 132.2, 130.0, 129.0, 127.9, 127.8,

120.3, 119.9, 118.7, 110.6, 50.1, 49.8; IR (v = cm⁻¹) : 3028, 3013, 2982, 2927, 1571, 1422, 1284, 825, 730; mp : 120-124°C.

N-Allyl-*N*-benzyl-4-fluoro-2-hydroxybenzamide (**12g**):

F OH

White solid, 77% Yield, ¹H NMR (CDCl₃, 500 MHz) δ 10,90-9.70 (br s, 1H), 7.41-7.27 (m, 6H), 6.70 (dd, J = 11.0 Hz, J = 2.5 Hz, 1H), 6.49 (td, J = 8.5 Hz, J = 2.5 Hz, 1H), 5.95-5.84 (m, 1H), 5.34 (d, J = 11.0 Hz, 1H), 5.26 (d, J = 17.0 Hz, 1H), 4.74 (s, 2H), 4.04 (d, J = 5.0 Hz, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ 172.0, 165.2 (d, J = 250.1 Hz), 161.3 (d, J = 13.0

Hz), 136.2, 132.4, 129.3 (d, J = 10.9 Hz), 129.0, 127.8, 127.6, 118.5, 113.9, 106.2 (d, J = 22.1 Hz), 105.1 (d, J = 24.0 Hz), 50.2, 50.1; IR ($v = cm^{-1}$) : 3060, 2029, 2959, 2887, 1614, 1578, 1431, 1280, 1155, 711; mp : 108-112°C.

N-Allyl-*N*-benzyl-3-hydroxy-2-naphthamide (**12h**):



White solid, 51% Yield, ¹H NMR (CDCl₃, 500 MHz) δ 9.35-8.95 (br s, 1H), 7.93-7.83 (br s, 1H), 7.67 (d, *J* = 8.0 Hz, 1H), 7.64-7.54 (br s, 1H), 7.50-7.27 (m, 8H), 5.99-5.90 (m, 1H), 5.37 (d, *J* = 10.5 Hz, 1H), 5.30 (d, *J* = 17.0 Hz, 1H), 4.82 (s, 2H), 4.11 (d, *J* = 5.0 Hz, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ 172.1, 154.4, 136.4, 136.1, 132.6, 129.1, 128.6, 128.2, 127.9,

127.8, 126.9, 126.5, 124.1, 120.2, 118.6, 112.4, 50.5, 50.1; IR (v = cm⁻¹) : 3116, 3085, 2982, 2894, 1594, 1488, 1221, mp : 162-167°C.

(4-Benzyl-5-oxo-1-tosyl-2,3,4,5-tetrahydro-1*H*-benzo[*e*][1,4]diazepin-2-yl)methylacetate (**2a**):



Pale yellow solid, 71 mg, 74% yield; ¹H NMR (CDCl₃, 250 MHz) δ 7.73 (dd, J = 8.0 Hz, J = 1.5 Hz, 1H), 7.60-7.42 (m, 5H), 7.30-7.25 (m, 5H), 7.18-7.12 (m, 2H), 4.74-4.66 (m, 2H), 4.15 (dd, J = 11.5 Hz, J = 5.5 Hz, 1H), 4.06 (dd, J = 11.5 Hz, J = 5.7 Hz, 1H), 3.52 (d, J = 14.7 Hz, 1H), 3.13 (dd, J = 15.2 Hz, J = 5.2 Hz, 1H), 3.00 (dd, J = 15.0 Hz, J = 11.5 Hz, 1H), 2.43 (s, 3H), 2.01 (s, 3H); ¹³C NMR

 $(CDCl_3, 62.5 \text{ MHz}) \delta$ 170.5, 167.8, 143.9, 136.5, 135.8, 134.7, 133.3, 132.9, 131.9, 130.3, 129.9, 129.4, 128.8, 128.1, 127.8, 127.3, 63.8, 59.9, 49.3, 46.8, 21.6, 20.7; MS (ESI) : m/z = 479.2 [M+H⁺]; HRMS (ESI) : m/z calcd for C₁₆H₂₇O₅N₂S [M+H⁺] 479.16352, found S16

479.16263; IR (v = cm⁻¹) : 3033, 2926, 2854, 1742, 1646, 1467, 1337, 1226, 1156; mp : 122-126°C.

(4-Benzyl-7-methyl-5-oxo-1-tosyl-2,3,4,5-tetrahydro-1*H*-benzo[*e*][1,4]diazepin-2-yl)methyl acetate (**2b**):



Pale yellow solid, 81 mg, 82% yield; ¹H NMR (CDCl₃, 250 MHz) δ 7.55-7.28 (m, 10H), 7.18-7.13 (m, 2H), 4.76-4.65 (m, 2H), 4.15 (dd, J = 11.2 Hz, J = 5.5 Hz, 1H), 4.07 (dd, J = 11.2 Hz, J = 5.7 Hz, 1H), 3.51 (d, J = 15.0 Hz, 1H), 3.12 (dd, J = 15.2 Hz, J = 5.2 Hz, 1H), 3.03 (dd, J = 15.0 Hz, J = 11.7 Hz, 1H), 2.44 (s, 6H), 2.04 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.7, 168.1, 144.0, 139.9, 136.6, 136.0, 134.4, 133.1, 132.8, 130.8, 130.2, 129.9, 128.8, 128.1, 127.9,

127.4, 63.9, 59.9, 49.4, 46.9, 21.7, 21.1, 20.8; MS (ESI) : $m/z = 493.2 [M+H^+]$; HRMS (ESI) : m/z calcd for $C_{27}H_{29}O_5N_2S [M+H^+]$ 493.17917, found 493.17819; IR ($\nu = cm^{-1}$) : 3038, 2925, 2854, 1746, 1630, 1443, 1253, 1225, 1163; mp : 192-196°C.

(4-Benzyl-5-oxo-1-tosyl-2,3,4,5-tetrahydro-1*H*-naphtho[2,3-*e*][1,4]diazepin-2-yl)methyl acetate (**2c**):



Brown solid, 73 mg, 69% yield; ¹H NMR (CDCl₃, 500 MHz) δ 8.26 (s, 1H), 8.02 (s, 1H), 7.93 (d, *J* = 9.0 Hz, 2H), 7.63-7.58 (m, 2H), 7.44 (d, *J* = 8.5 Hz, 2H), 7.33-7.24 (m, 5H), 7.19 (d, *J* = 8.5 Hz, 2H), 4.79 (d, *J* = 15.5 Hz, 1H), 4.79-4.74 (m, 1H), 4.16 (dd, *J* = 11.5 Hz, *J* = 5.5 Hz, 1H), 4.11 (dd, *J* = 11.5 Hz, *J* = 6.5 Hz, 1H), 3.63 (d, *J* = 15.0 Hz, 1H), 3.17 (dd, *J* = 15.5 Hz, *J* = 4.5 Hz, 1H), 3.02 (dd, *J* = 15.5 Hz, *J* = 12.5 Hz, 1H), 2.41 (s, 3H), 2.02 (s, 3H);

¹³C NMR (CDCl₃, 125 MHz) δ 170.7, 167.9, 144.0, 136.7, 136.2, 134.7, 132.8, 132.7, 132.3, 131.6, 129.9, 129.0, 128.9, 128.7, 128.3, 128.2, 127.9, 127.4, 63.6, 59.4, 49.6, 46.8, 21.7, 20.9; MS (ESI) : $m/z = 529.1 [M+H^+]$; HRMS (ESI) : m/z calcd for C₃₀H₂₉O₅N₂S [M+H⁺] 529.17917, found 529.17798; IR ($\nu = cm^{-1}$) : 3031, 2924, 2854, 1742, 1651, 1473, 1351, 1229, 1163; mp : 86-90°C.

(4-Benzyl-8-methoxy-5-oxo-1-tosyl-2,3,4,5-tetrahydro-1*H*-benzo[*e*][1,4]diazepin-2-yl)methyl acetate (**2d**):



Pale yellow solid, 72 mg, 71% yield; ¹H NMR (CDCl₃, 250 MHz) δ 7.67 (d, J = 8.5 Hz, 1H), 7.49 (d, J = 8.2 Hz, 2H), 7.35-7.25 (m, 5H), 7.20-7.10 (m, 2H), 7.06-6.99 (m, 2H), 4.73-4.62 (m, 2H), 4.20-4.06 (m, 2H), 3.91 (s, 3H), 3.49 (d, J = 14.7 Hz, 1H), 3.13 (dd, J = 15.2 Hz, J = 5.5 Hz, 1H), 3.03 (dd, J = 15.5 Hz, J = 12.0 Hz, 1H), 2.44 (s, 3H), 2.05 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.6, 167.9, 162.3, 144.0, 136.7, 135.8, 134.5, 131.6, 129.9, 128.8, 128.1,

127.8, 127.3, 126.8, 118.1, 115.5, 63.8, 60.0, 55.8, 49.3, 46.8, 21.6, 20.8; MS (ESI) : $m/z = 509.1 \text{ [M+H^+]}$; HRMS (ESI) : m/z calcd for $C_{27}H_{29}O_6N_2S$ [M+H⁺] 509.1741, found 509.1738; IR ($\nu = \text{cm}^{-1}$) : 3071, 2922, 2853, 1745, 1627, 1432, 1242, 1221, 1174, 1164; mp : dec. 125°C.

(4-Benzyl-7-methoxy-5-oxo-1-tosyl-2,3,4,5-tetrahydro-1*H*-benzo[*e*][1,4]diazepin-2-yl)methyl acetate (**2e**):



Pale yellow solid, 69 mg, 68% yield; ¹H NMR (CDCl₃, 500 MHz) δ 7.45 (d, *J* = 8.0 Hz, 2H), 7.40 (d, *J* = 9.0 Hz, 1H), 7.32-7.25 (m, 5H), 7.19 (d, *J* = 3.0 Hz, 1H), 7.14 (d, *J* = 8.0 Hz, 2H), 7.05 (dd, *J* = 8.5 Hz, *J* = 3.0 Hz, 1H), 4.68 (d, *J* = 14.5 Hz, 1H), 4.68-4.64 (m, 1H), 4.11 (dd, *J* = 11.5 Hz, *J* = 5.5 Hz, 1H), 4.04 (dd, *J* = 11.5 Hz, *J* = 6.0 Hz, 1H), 3.86 (s, 3H), 3.49 (d, *J* = 15.0 Hz, 1H), 3.09 (dd, *J* = 15.0 Hz, *J* = 4.5 Hz, 1H), 2.98 (dd, *J* = 15.5 Hz, *J* = 12.5

Hz, 1H), 2.42 (s, 3H), 2.01 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.7, 167.8, 160.2, 144.0, 136.6, 136.0, 135.9, 134.6, 130.0, 128.9, 128.2, 127.9, 127.4, 125.4, 118.4, 114.4, 63.8, 59.9, 55.9, 49.5, 46.9, 21.7, 20.9; MS (ESI) : m/z = 509.2 [M+H⁺]; HRMS (ESI) : m/z calcd for C₂₇H₂₉O₆N₂S [M+H⁺] 509.17408, found 509.17313; IR (v = cm⁻¹) : 3025, 2925, 2857, 1745, 1635, 1483, 1236, 1218, 1162, 1029; mp : 184-188°C.

(4-Benzyl-7,8-dimethoxy-5-oxo-1-tosyl-2,3,4,5-tetrahydro-1*H*-benzo[*e*][1,4]diazepin-2-yl) methyl acetate (**2f**):



Pale yellow solid, 75 mg, 70% yield; ¹H NMR (CDCl₃, 500 MHz) δ 7.47 (d, *J* = 8.0 Hz, 2H), 7.33-7.25 (m, 5H), 7.17 (s, 1H), 7.16 (d, *J* = 7.5 Hz, 2H), 6.99 (s, 1H), 4.72-4.67 (m, 1H), 4.64 (d, *J* = 14.5 Hz, 1H), 4.12 (d, *J* = 5.5 Hz, 2H), 3.96 (s, 3H), 3.95 (s, 3H), 3.49 (d, *J* = 15.0 Hz, 1H), 3.11 (dd, *J* = 15.0 Hz, *J* = 5.0 Hz, 1H), 3.03 (dd, *J* = 15.5 Hz, *J* = 12.0 Hz, 1H), 2.43 (s, 3H), 2.04 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.6, 167.9, 151.4, 149.6, 144.0,

136.7, 135.7, 129.9, 128.8, 128.2, 127.8, 127.4, 126.8, 126.4, 115.7, 111.8, 63.8, 60.4, 56.4, 56.3, 49.5, 46.9, 21.7, 20.9; MS (ESI) : $m/z = 539.1 [M+H^+]$; HRMS (ESI) : m/z calcd for $C_{28}H_{31}O_7N_2S [M+H^+] 539.18465$, found 539.18359; IR ($\nu = cm^{-1}$) : 3013, 2967, 2901, 1747, 1631, 1427, 1244, 1218, 1163, 1146; mp : 136-140°C.

(4-Benzyl-8-chloro-5-oxo-1-tosyl-2,3,4,5-tetrahydro-1*H*-benzo[*e*][1,4]diazepin-2-yl)methyl acetate (**2g**):



Red-yellow oil, 69 mg, 67% yield; ¹H NMR (CDCl₃, 500 MHz) δ 7.56 (d, *J* = 8.5 Hz, 1H), 7.47 (d, *J* = 2.0 Hz, 1H), 7.38 (d, *J* = 8.0 Hz, 3H), 7.24-7.19 (m, 5H), 7.06-7.04 (m, 2H), 4.62-4.56 (m, 2H), 4.11 (dd, *J* = 11.5 Hz, *J* = 5.5 Hz, 1H), 3.95 (dd, *J* = 11.5 Hz, *J* = 5.0 Hz, 1H), 3.44 (d, *J* = 15.0 Hz, 1H), 3.04 (dd, *J* = 15.5 Hz, *J* = 5.0 Hz, 1H), 2.93 (dd, *J* = 15.5 Hz, *J* = 12.5 Hz, 1H), 2.34 (s, 3H), 1.92 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.6, 166.9, 144.4,

137.7, 136.3, 135.6, 134.3, 133.3, 133.2, 131.4, 130.1, 129.8, 128.9, 128.2, 128.0, 127.4, 63.9, 60.2, 49.5, 46.8, 21.7, 20.7; MS (ESI) : $m/z = 513.1 [M+H^+]$; HRMS (ESI) : m/z calcd for $C_{26}H_{26}O_5N_2ClS [M+H^+] 513.12455$, found 513.12354; IR ($v = cm^{-1}$) : 3030, 2922, 1746, 1635, 1351, 1219, 1159.

(4-Benzyl-7-bromo-5-oxo-1-tosyl-2,3,4,5-tetrahydro-1*H*-benzo[*e*][1,4]diazepin-2-yl)methyl acetate (**2h**):



Pale yellow solid, 68 mg, 61% yield; ¹H NMR (CDCl₃, 500 MHz) δ 7.84 (d, J = 2.5 Hz, 1H), 7.67 (dd, J = 8.5 Hz, J = 2.5 Hz, 1H), 7.45 (d, J = 8.0 Hz, 2H), 7.40 (d, J = 8.5 Hz, 1H), 7.32-7.27 (m, 5H), 7.13-7.11 (m, 2H), 4.69 (d, J = 14.5 Hz, 1H), 4.68-4.64 (m, 1H), 4.13 (dd, J = 11.5 Hz, J = 5.5 Hz, 1H), 4.04 (dd, J = 11.5 Hz, J = 5.5 Hz, 1H), 3.49 (d, J = 15.0 Hz, 1H), 3.12 (dd, J = 15.5 Hz, J = 5.0 Hz, 1H), 2.99 (dd, J = 15.5 Hz, J = 12.5 Hz, 1H), 2.43

(s, 3H), 2.01 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.6, 166.5, 144.4, 136.4, 136.3, 135.7, 135.2, 134.9, 133.4, 132.1, 130.1, 128.9, 128.2, 128.1, 127.4, 123.7, 63.9, 60.1, 49.6, 46.8, 21.8, 20.9; MS (ESI) : m/z = 557.0 [M+H⁺]; HRMS (ESI) : m/z calcd for C₂₆H₂₆O₅N₂BrS [M+H⁺] 557.07403, found 557.07330; IR (v = cm⁻¹) : 3011, 2923, 2854, 1749, 1634, 1362, 1222, 1170; mp : 210-214°C.

(4-Benzyl-8-nitro-5-oxo-1-tosyl-2,3,4,5-tetrahydro-1*H*-benzo[*e*][1,4]diazepin-2-yl)methyl acetate (**2i**):



Pale yellow solid, 61 mg, 58% yield; ¹H NMR (CDCl₃, 500 MHz) δ 8.36 (d, J = 2.0 Hz, 1H), 8.30 (dd, J = 8.0 Hz, J = 2.0 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.45 (d, J = 8.5 Hz, 2H), 7.33-7.28 (m, 5H), 7.15-7.12 (m, 2H), 4.69 (d, J = 14.5 Hz, 1H), 4.71-4.67 (m, 1H), 4.23 (dd, J = 11.5 Hz, J = 5.0 Hz, 1H), 4.05 (dd, J = 11.5 Hz, J = 4.5 Hz, 1H), 3.58 (d, J = 15.0 Hz, 1H), 3.18 (dd, J = 15.5

Hz, J = 4.5 Hz, 1H), 3.02 (dd, J = 15.5 Hz, J = 12.5 Hz, 1H), 2.43 (s, 3H), 1.96 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.5, 165.9, 149.8, 144.8, 140.5, 135.8, 135.4, 134.8, 131.6, 130.3, 129.0, 128.5, 128.3, 128.2, 127.4, 124.0, 64.1, 60.3, 49.6, 46.7, 21.7, 20.7; MS (ESI) : m/z = 524.1 [M+H⁺]; HRMS (ESI) : m/z calcd for C₂₆H₂₆O₇N₃S [M+H⁺] 524.14860, found 524.14746; IR (v = cm⁻¹) : 3035, 2923, 2853, 1745, 1657, 1527, 1435, 1349, 1255, 1162; mp : 136-142°C.

(4-Benzyl-7-nitro-5-oxo-1-tosyl-2,3,4,5-tetrahydro-1*H*-benzo[*e*][1,4]diazepin-2-yl)methyl acetate (**2j**):



Pale yellow solid, 64 mg, 61% yield; ¹H NMR (CDCl₃, 500 MHz) δ 8.55 (d, J = 2.5 Hz, 1H), 8.36 (dd, J = 8.5 Hz, J = 3.0Hz, 1H), 7.75 (d, J = 9.0 Hz, 1H), 7.44 (d, J = 8.0 Hz, 2H), 7.33-7.28 (m, 5H), 7.15-7.13 (m, 2H), 4.71 (d, J = 15.5 Hz, 1H), 4.72-4.67 (m, 1H), 4.19 (dd, J = 12.0 Hz, J = 5.5 Hz, 1H), 4.07 (dd, J = 11.5 Hz, J = 5.0 Hz, 1H), 3.57 (d, J = 14.5 Hz, 1H),3.18 (dd, J = 15.5 Hz, J = 4.5 Hz, 1H), 3.05 (dd, J = 15.5 Hz, J

= 12.0 Hz, 1H), 2.44 (s, 3H), 1.98 (s, 3H); 13 C NMR (CDCl₃, 125 MHz) δ 170.4, 165.7, 147.9, 144.9, 138.9, 136.1, 135.8, 135.3, 134.6, 130.3, 129.0, 128.3, 127.3, 126.3, 125.9, 64.1, 60.6, 49.6, 46.6, 21.7, 20.7; MS (ESI) : $m/z = 524.1 [M+H^+]$; HRMS (ESI) : m/z calcd for $C_{26}H_{26}O_7N_3S$ [M+H⁺] 524.14860, found 524.14771; IR (v = cm⁻¹) : 3013, 2968, 2901, 1748, 1637, 1529, 1446, 1352, 1221, 1164; mp : 128-132°C.

4-Benzyl-2-(hydroxymethyl)-1,2,3,4-tetrahydro-5*H*-benzo[e][1,4]diazepin-5-one (11):

OH

Pale yellow oil, 133 mg, 75% yield, ¹H NMR (CDCl₃, 500 MHz) δ 7.81 (dd, J = 8.0 Hz, J = 1.5 Hz, 1H), 7.34-7.24 (m, 5H), 7.23-7.19 (m, 1H), 6.88 (td, J = 8.0 Hz, J = 0.5 Hz, 1H), 6.62 (dd, J = 8.0 Hz, J = 0.5Hz, 1H), 4.94 (d, J = 15.0 Hz, 1H), 4.61 (d, J = 15.0 Hz, 1H), 3.65-

3.54 (m, 1H), 3.47 (dd, J = 10.5 Hz, J = 5.5 Hz, 1H), 3.40 (dd, J = 10.5 Hz, J = 7.5 Hz, 1H),3.35 (dd, J = 15.0 Hz, J = 7.0 Hz, 1H), 3.30 (dd, J = 15.0 Hz, J = 3.5 Hz, 1H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.6, 144.4, 137.2, 132.5, 132.0, 128.8, 128.3, 127.7, 123.1, 120.0, 119.9, 63.9, 61.4, 51.8, 46.9; MS (ESI) : $m/z = 283.2 [M+H^+]$; HRMS (ESI) : m/z calcd for $C_{17}H_{19}O_2N_2$ $[M+H^+]$ 283.1441, found 283.1436; IR (v = cm⁻¹) : 3338, 3030, 2923, 2852, 1615, 1480.

(4-Benzyl-5-oxo-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepin-2-yl)methyl acetate (**13a**):



Pale yellow oil, 46 mg, 71% yield; ¹H NMR (CDCl₃, 500 MHz) δ 7.83 (dd, *J* = 8.0 Hz, *J* = 2.0 Hz, 1H), 7.41 (td, *J* = 7.5 Hz, *J* = 1.5 Hz, 1H), 7.37-7.32 (m, 4H), 7.31-7.28 (m, 1H), 7.20 (td, J = 7.5 Hz, J = 1.0 Hz,1H), 6.99 (dd, J = 7.5 Hz, J = 1.0 Hz, 1H), 5.05 (d, J = 15.0 Hz, 1H), 4.62 (d, J = 15.0 Hz, 1H), 4.45-4.40 (m, 1H), 4.14 (dd, J = 12.0 Hz, J

= 6.0 Hz, 1H), 4.04 (dd, *J* = 12.0 Hz, *J* = 5.0 Hz, 1H), 3.44 (dd, *J* = 16.0 Hz, *J* = 9.0 Hz, 1H), 3.32 (dd, J = 16.0 Hz, J = 4.0 Hz, 1H), 2.01 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.5, 168.8, 152.5, 136.9, 132.9, 130.9, 128.9, 128.3, 128.0, 127.9, 124.4, 122.5, 80.9, 63.2, 51.1, 46.9, 20.8; MS (ESI) : $m/z = 326.2 [M+H^+]$; HRMS (ESI) : m/z calcd for $C_{19}H_{20}O_4N [M+H^+]$ 326.1387, found 326.1378; IR ($\nu = cm^{-1}$) : 3032, 2927, 2854, 1743, 1640, 1469, 1237, 1207.

(4-Benzyl-7-methyl-5-oxo-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepin-2-yl)methyl acetate (**13b**):



Pale yellow oil, 48 mg, 70% yield; ¹H NMR (CDCl₃, 500 MHz) δ 7.61 (d, J = 2.0 Hz, 1H), 7.38-7.31 (m, 4H), 7.31-7.27 (m, 1H), 7.21 (dd, J = 8.0 Hz, J = 1.5 Hz, 1H), 6.88 (d, J = 7.5 Hz, 1H), 5.03 (d, J= 14.5 Hz, 1H), 4.63 (d, J = 14.5 Hz, 1H), 4.43-4.37 (m, 1H), 4.14 (dd, J = 12.0 Hz, J = 6.0 Hz, 1H), 4.02 (dd, J = 12.0 Hz, J = 5.5 Hz,

1H), 3.41 (dd, J = 15.5 Hz, J = 8.5 Hz, 1H), 3.30 (dd, J = 15.5 Hz, J = 3.5 Hz, 1H), 2.35 (s, 3H), 2.02 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.5, 169.1, 150.2, 137.0, 134.2, 133.6, 130.9, 128.9, 128.3, 127.9, 127.8, 122.3, 80.8, 63.2, 51.0, 46.9, 20.8, 20.7; MS (ESI) : m/z = 340.3 [M+H⁺]; HRMS (ESI) : m/z calcd for C₂₀H₂₂O₄N [M+H⁺] 340.1543, found 340.1536; IR ($v = cm^{-1}$) : 3031, 2924, 2854, 1743, 1645, 1488, 1218.

(4-Benzyl-9-methyl-5-oxo-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepin-2-yl)methyl acetate (**13c**):



Pale yellow oil, 41 mg, 60% yield; ¹H NMR (CDCl₃, 500 MHz) δ 7.63 (d, *J* = 7.5 Hz, 1H), 7.38-7.32 (m, 4H), 7.32-7.28 (m, 2H), 7.09 (t, *J* = 7.5 Hz, 1H), 5.07 (d, *J* = 15.0 Hz, 1H), 4.60 (d, *J* = 15.0 Hz, 1H), 4.47-4.41 (m, 1H), 4.11 (dd, *J* = 12.0 Hz, *J* = 6.0 Hz, 1H), 4.01 (dd, *J* = 12.0 Hz, *J* = 5.5 Hz, 1H), 3.43 (dd, *J* = 15.5 Hz, *J* = 8.0 Hz,

1H), 3.32 (dd, J = 15.5 Hz, J = 4.0 Hz, 1H), 2.23 (s, 3H), 2.02 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.5, 169.2, 150.6, 137.1, 134.3, 134.2, 131.1, 128.9, 128.5, 128.3, 127.9, 124.1, 124.1, 80.9, 63.7, 51.0, 46.8, 20.8, 16.1; MS (ESI) : m/z = 340.3 [M+H⁺]; HRMS (ESI) : m/z calcd for C₂₀H₂₂O₄N [M+H⁺] 340.1543, found 340.1536; IR (v = cm⁻¹) : 3030, 2924, 2854, 1743, 1641, 1421, 1236, 1203.

(4-Benzyl-7-methoxy-5-oxo-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepin-2-yl)methylacetate (**13d**):



Pale yellow oil, 25 mg, 35% yield; ¹H NMR (CDCl₃, 500 MHz) δ 7.39-7.27 (m, 6H), 6.96 (dd, *J* = 9.0 Hz, *J* = 3.5 Hz, 1H), 6.92 (d, *J* = 9.0 Hz, 1H), 5.04 (d, *J* = 15.0 Hz, 1H), 4.62 (d, *J* = 15.0 Hz, 1H), 4.42-4.34 (m, 1H), 4.13 (dd, *J* = 12.0 Hz, *J* = 6.0 Hz, 1H), 4.02 (dd, *J* = 12.0 Hz, *J* = 5.5 Hz, 1H), 3.82 (s, 3H), 3.40

 $(dd, J = 15.5 Hz, J = 8.5 Hz, 1H), 3.30 (dd, J = 15.5 Hz, J = 4.5 Hz, 1H), 2.02 (s, 3H); {}^{13}C NMR$ (CDCl₃, 125 MHz) δ 170.5, 168.9, 156.4, 145.9, 136.9, 128.9, 128.3, 127.9, 123.6, 119.7, 113.8, 80.8, 63.1, 55.9, 51.1, 46.9, 20.8; MS (ESI) : m/z = 356.3 [M+H⁺]; HRMS (ESI) : m/z calcd for C₂₀H₂₂O₅N [M+H⁺] 356.1492, found 356.1483; IR (v = cm⁻¹) : 3030, 2936, 2852, 1742, 1645, 1488, 1197.

(4-Benzyl-7-chloro-5-oxo-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepin-2-yl)methyl acetate (**13e**):



Pale yellow oil, 43 mg, 60% yield; ¹H NMR (CDCl₃, 500 MHz) δ 7.81 (d, J = 2.5 Hz, 1H), 7.38-7.28 (m, 6H), 6.94 (d, J = 9.0 Hz, 1H), 5.02 (d, J = 15.0 Hz, 1H), 4.61 (d, J = 15.0 Hz, 1H), 4.45-4.38 (m, 1H), 4.13 (dd, J = 12.0 Hz, J = 5.5 Hz, 1H), 4.03 (dd, J = 12.0Hz, J = 5.0 Hz, 1H), 3.44 (dd, J = 16.0 Hz, J = 8.5 Hz, 1H), 3.33

(dd, J = 16.0 Hz, J = 4.0 Hz, 1H), 2.01 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.4, 167.4, 151.2, 136.6, 132.8, 130.7, 129.7, 129.1, 129.0, 128.3, 128.1, 123.9, 81.1, 63.1, 51.2, 46.8, 20.8; MS (ESI) : m/z = 360.2 [M+H⁺]; HRMS (ESI) : m/z calcd for C₁₉H₁₉O₄NCl [M+H⁺] 360.0997, found 360.0980; IR (v = cm⁻¹) : 3031, 2926, 2854, 1744, 1647, 1470, 1210.

(4-Benzyl-7-bromo-5-oxo-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepin-2-yl)methyl acetate (**13f**):



Pale yellow oil, 48 mg, 60% yield; ¹H NMR (CDCl₃, 500 MHz) δ 7.96 (d, J = 2.0 Hz, 1H), 7.50 (dd, J = 9.0 Hz, J = 2.5 Hz, 1H), 7.40-7.27 (m, 5H), 6.88 (d, J = 9.0 Hz, 1H), 5.01 (d, J = 15.5 Hz, 1H), 4.61 (d, J = 15.0 Hz, 1H), 4.46-4.38 (m, 1H), 4.13 (dd, J =12.0 Hz, J = 6.0 Hz, 1H), 4.03 (dd, J = 12.0 Hz, J = 5.0 Hz, 1H),

3.44 (dd, J = 15.5 Hz, J = 8.0 Hz, 1H), 3.33 (dd, J = 15.5 Hz, J = 4.0 Hz, 1H), 2.01 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ : 170.4, 167.3, 151.7, 136.6, 135.8, 133.7, 129.4, 129.0, 128.3, 128.1, 124.3, 117.1, 81.1, 63.2, 51.2, 46.8, 20.8; MS (ESI) : m/z = 404.2 [M+H⁺]; HRMS (ESI) : m/z calcd for C₁₉H₁₉O₄NBr [M+H⁺] 404.0492, found 404.0485; IR (ν = cm⁻¹) : 3030, 2924, 2854, 1744, 1647, 1468, 1210.

(4-Benzyl-8-fluoro-5-oxo-2,3,4,5-tetrahydrobenzo[*f*][1,4]oxazepin-2-yl)methyl acetate (**13g**):



Beige solid, 43 mg, 63% yield; ¹H NMR (CDCl₃, 500 MHz) δ 7.87 (dd, *J* = 9.0 Hz, *J* = 6.5 Hz, 1H), 7.38-7.28 (m, 5H), 6.91 (td, *J* = 8.0 Hz, *J* = 2.5 Hz, 1H), 6.71 (dd, *J* = 9.5 Hz, *J* = 2.5 Hz, 1H), 5.04 (d, *J* = 15.5 Hz, 1H), 4.59 (d, *J* = 15.5 Hz, 1H), 4.45-4.39 (m, 1H), 4.14 (dd, *J* = 12.0 Hz, *J* = 5.0 Hz, 1H), 4.05 (dd, *J* = 12.0 Hz, *J* =

5.0 Hz, 1H), 3.48 (dd, J = 15.5 Hz, J = 9.0 Hz, 1H), 3.35 (dd, J = 15.5 Hz, J = 4.0 Hz, 1H), 2.02 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.4, 167.8, 165.3 (d, J = 250.5 Hz), 154.4 (d, J = 12.6 Hz), 136.8, 133.1 (d, J = 9.9 Hz), 129.0, 128.4, 128.1, 123.5 (d, J = 3.1 Hz), 111.7 (d, J = 21.2 Hz), 109.5 (d, J = 23 Hz), 81.3, 63.3, 51.2, 47.0, 20.8; ¹⁹F NMR (CDCl₃, 470 MHz) δ -106.5; MS (ESI) : m/z = 344.2 [M+H⁺]; HRMS (ESI) : m/z calcd for C₁₉H₁₉O₄NF [M+H⁺] 344.1293, found 344.1285; IR (v = cm⁻¹) : 3031, 2923, 2853, 1732, 1643, 1434, 1260; mp : 102-106°C.

(4-Benzyl-5-oxo-2,3,4,5-tetrahydronaphtho[2,3-*f*][1,4]oxazepin-2-yl)methyl acetate (**13h**):



Pale yellow oil, 45 mg, 60% yield; ¹H NMR (CDCl₃, 500 MHz) δ 8.37 (s, 1H), 7.91 (d, *J* = 8.5 Hz, 1H), 7.77 (d, *J* = 8.0 Hz, 1H), 7.53 (t, *J* = 7.5 Hz, 1H), 7.46 (t, *J* = 7.5 Hz, 1H), 7.44 (s, 1H), 7.40-7.35 (m, 4H), 7.35-7.29 (m, 1H), 5.09 (d, *J* = 15.0 Hz, 1H), 4.70 (d, *J* = 15.0 Hz, 1H), 4.50-4.42 (m, 1H), 4.22 (dd, *J* = 11.5

Hz, J = 6.0 Hz, 1H), 4.07 (dd, J = 11.5 Hz, J = 5.0 Hz, 1H), 3.42 (dd, J = 16.0 Hz, J = 8.5 Hz, 1H), 3.35 (dd, J = 16.0 Hz, J = 4.0 Hz, 1H), 2.05 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ 170.6, 168.9, 148.9, 137.0, 135.8, 131.7, 130.6, 129.1, 129.0, 128.9, 128.3, 128.1, 128.0, 127.0, 125.9, 119.5, 80.3, 62.9, 51.1, 46.8, 20.9; MS (ESI) : m/z = 376.3 [M+H⁺]; HRMS (ESI) : m/z calcd for C₂₃H₂₂O₄N [M+H⁺] 376.1543, found 376.1533; IR (v = cm⁻¹) : 3030, 2925, 2853, 1742, 1650, 1454, 1215.

IV. ¹H and ¹³C NMR spectra



























































































